Researchers, publishing in the European Heart Journal, identified 40 common cardiovascular biomarkers in 638 consecutive patients admitted with known AFib or two or more CHA2DS2-VASc risk factors. The employed logistic regression with forward selection and machine learning algorithms to determine clinical risk factors as well as biomarkers associated with AFib.
Pleasant surprise for Monday. Joint first author in this European Heart Journal article. Novel biomarkers for AF. https://t.co/XytaBo56JN
— Yanish (@Yanish12) January 7, 2019
Biomarkers identified to help diagnose heart condition❗ https://t.co/ELJ5IpMMCy 3 simple clinical risk factors (age, sex, and BMI) and two biomarkers (elevated BNP and elevated FGF-23) identify patients with AF https://t.co/KXHyAIsNLG AF affects around 1.6m people in the UK❗
— Reiner Grißhammer (@erlesen) January 8, 2019
According to their results, AFib correlated significantly (and exclusively) with age (P=0.001), male sex (P=0.008), BMI (P=0.003), elevated BNP levels (P=0.002), elevated FGF-23 (P=0.001), and reduced TRAIL-R2 (P=0.001). These biomarkers helped improve prediction of AFib when compared to just looking at clinical factors alone (P<0.001).
— Oxford Medicine (@OUPMedicine) January 9, 2019
“ECG screening is resource-intensive and burdensome for patients therefore it is important that the right patients are selected for this type of screening,” lead author Yanish Purmah, MD, of the University of Birmingham, concluded in a press release. “The biomarkers we have identified have the potential to be used in a blood test in community settings such as in general practices to simplify patient selection for ECG screening.”
A new European Heart Journal publication examines if biomarkers can identify undetected atrial fibrillation. Nice potential but not too convincing precision at the moment, despite 700-ish patients #Cardiology #Atrialfibrillation #MachineLearning https://t.co/awIER2hwgf
— Christian Kruse (@ckrusemd) January 9, 2019
Coauthor Paulus Kirchhof, MD, Director of the University of Birmingham’s Institute of Cardiovascular Sciences, added that “[w]e hope that, as the result of our findings, more people with what can often be a silent disease are diagnosed so that any complications can be prevented.”
PUBLICATION: "Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation", published today in @ESC_Journals https://t.co/cwUIb69tlG @afnet_ev pic.twitter.com/ZKqIHhlkJK
— UoB Cardiovascular (@ICVS_UoB) January 7, 2019
Source: European Heart Journal